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Abstract— Drug repositioning offers an effective solution to drug discovery, saving both time and 
resources by finding new indications for existing drugs. Typically, a drug takes effect via its protein 
targets in the cell. As a result, it is necessary for drug development studies to conduct an investigation into 
the interrelationships of drugs, protein targets, and diseases. Although previous studies have made a 
strong case for the effectiveness of integrative network-based methods for predicting these 
interrelationships, little progress has been achieved in this regard within drug repositioning research. 
Moreover, the interactions of new drugs and targets (lacking any known targets and drugs, respectively) 
cannot be accurately predicted by most established methods. 
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In this paper, we propose a novel semi-supervised heterogeneous label propagation algorithm named 
Heter-LP, which applies both local as well as global network features for data integration. To predict 
drug-target, disease-target, and drug-disease associations, we use information about drugs, diseases, and 
targets as collected from multiple sources at different levels. Our algorithm integrates these various types 
of data into a heterogeneous network and implements a label propagation algorithm to find new 
interactions. Statistical analyses of 10-fold cross-validation results and experimental analysis support the 
effectiveness of the proposed algorithm. 
 
Keywords—semi-supervised learning; heterogeneous networks; label propagation; drug-disease 
associations; drug–target interactions; disease-target interactions. 
 
1 Introduction 
The process of finding additional indications for existing drugs is known as Drug Repositioning (DR).  
DR is a way to save time and costs when compared to the de novo drug development process. 
Computational methods can guide wet lab experimental design by narrowing the scope of candidate 
targets to accelerate drug discovery and can provide supporting evidence for experimental results. 
Recent research shows that simultaneous use of the three concepts of diseases, drugs, and targets 
together leads to better results for drug repositioning [1]. Specifically, the application of network-based 
approaches in the fields of genomics, transcriptomics, proteomics, and systems biology have potential to 
improve drug development. These improvements will help decrease the time between lead development 
and drug marketability [2]. 
Advances in the biological sciences over the past several decades have resulted in the generation of 
large amounts of molecular data at the level of the genome, transcriptome, proteome, and metabolome, 
motivating the application of data-driven approaches. One of the most frequently used data-driven 
approaches is network modeling. However, each type of molecular data presents a limited view of the 
biological system. Hence, the combination of multiple data types can provide a more enriched and 
complete picture. Multilevel systems integration has been successfully applied to combine these 
heterogeneous data types into integrated networks in other application areas; for example, such 
integration has enabled efficient modeling of metabolic perturbation [3], [4], [5]. The use of 
heterogeneous networks in DR is motivated by the fact that drugs tend to take effect via interaction with 
one or more protein targets within a cell. Therefore, it is necessary to consider drugs, protein targets, and 
diseases simultaneously to investigate their inter-relationships. 
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The research objective of this paper is to provide a computational framework to facilitate drug 
repositioning tasks based on a heterogeneous network, generated by integrating drug, disease, and target 
information in different levels. 
Specifically, this work includes two components. (1) Construction of a heterogeneous network: This 
network is composed of six networks: the drug similarity network, disease similarity network, target 
similarity network, known drug-disease associations, known drug–target interactions and known disease-
target interactions. (2) Algorithmic prediction of different potential interactions: We here develop a 
heterogeneous label propagation algorithm to predict potential drug–target interactions, drug-disease 
associations, and disease-target interactions by integrating multi-source information. The reason for this 
choice is that heterogeneous network label propagation is an effective and efficient technique to utilize 
both local and global features in a network for semi-supervised learning [6]. We introduce a novel semi-
supervised heterogeneous label propagation algorithm named Heter-LP. The Heter-LP algorithm consists 
of the following steps: (1) Data collection and preparation, (2) construction of similarity matrices and 
association matrices, and (3) label propagation. Then we use Heter-LP to develop a new drug 
repositioning method, by performing label propagation to integrate different levels of biological 
information and apply an optimization algorithm to find new drug-target interactions. The evaluation is 
based on a 10-fold cross-validation experiment design and we analyze the results using performance 
metrics such as the Area Under the Receiver Operating Characteristic Curve (AUC) and Area Under the 
Precision-Recall curve (AUPR).  
The goals of this research are to identify putative candidates for drug repositioning, to further improve 
the prediction accuracy of drug-target interactions, and to discover useful drug-disease and disease-target 
associations. In this application, the inputs to our algorithm are three similarity matrices and three 
association matrices which are generated using three different levels of information (molecular originated 
profiles, molecular activity information, and phenotypic properties). The primary output will be three 
matrices representing drug-target interactions, drug-disease associations, and disease-target associations. 
The final output is a ranked list of candidates for drug repositioning. Secondary outputs include new 
similarity matrices for drugs, diseases, and targets which could have application in clustering for example. 
Unlike existing methods, our proposed method can predict interactions of new drugs (where a drug has 
no known target) and new targets (where a target has no known drug). Moreover, in our approach, there is 
no requirement for negative training exemplars. The other benefit of the proposed method is its ability to 
predict both trivial and non-trivial interactions. We believe that meaningful and efficient integration of 
information is achieved due to our use of an appropriate structural network model and suitable label 
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propagation algorithm. Moreover, the pre-phase projection phase enriches the algorithm. The statistical 
and experimental analysis will demonstrate these claims. 
The paper is organized as follows. Section 2 presents the related work. A complete description of our 
proposed method is provided in Section 3. Section 4 proves the convergence of the method. In Section 5, 
the regularization framework is presented. The performance evaluation and a brief description of 
computational and time complexity of the algorithm is presented in Section 6. Finally, Section 7 provides 
a summary of the research. 
2 Related Work 
Gene expression patterns change systematically in response to disease processes. Transcriptome data 
provide a snapshot of such whole-genome dynamics and can provide insights into the mechanism of 
action of drugs [7]. Differential gene expression analysis is an effective way to identify genes that lead to 
disease. In this regard, some drug repositioning methods have been developed based on gene expression 
analysis, such as [8], [9], [10], [11], [12], [13], [14]. In spite of observed good performance, there are 
limitations associated with these methods that compare gene expression signatures. First, the set of drugs 
and diseases included in current databases of gene expressions are limited, so these methods are restricted 
to the subset of known diseases (such as particular kinds of cancers). So it seems that we cannot rely 
solely on such limited data and we need more data sources to complement them. Second, results coming 
from cell lines cannot always be extrapolated to in vivo tissues. 
Protein-protein interaction (PPI) is often used as the basis for drug target identification since the PPI 
network provides the context in which the target protein operates. Here, there is an underlying assumption 
that the proteins targeted by similar drugs tend to be functionally associated and be close in the PPI 
network. Here, a similar drug refers to a drug that has “similar therapeutic effects” [7]. Some of the most 
important drug repositioning methods based on PPI include refs [15] and [16]. Despite demonstrated 
success in repositioning drugs using PPI networks, there are also some limitations. First, the required PPI 
data are noisy and incomplete, and the extracted networks are incomplete and biased [17]. Second, like 
gene regulatory networks, there is no simple mapping between a simulated network and a living 
organism’s actual response [17]. 
By using a metabolic network, several important physiological properties of a cell could be 
extrapolated. So metabolic networks can also be used to predict drug targets. Two drug repositioning 
methods based on metabolic networks are described in [18] and [19]. 
The identification of novel drug-target interactions (DTI) is the basis for drug discovery and design, 
and accurate prediction of drug targets is a key to effective drug repositioning. Many drugs are non-
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specific and show reactivity to additional targets besides the primary targets. Although these off-target 
effects often leading to unwanted side effects (discussed below), these one-drug-multiple-target data can 
also be leveraged by DR methods. Motivated by this, researchers have developed many methods based on 
drug-target interactions, including [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], 
[33], [34]. Some of these methods are based strictly on DTI, while others are extended to leverage 
additional data such as protein-protein similarity and drug-drug similarity1, often leading to increased 
performance. For example, when a given drug has several known targets, additional candidate targets can 
be ranked by calculating the similarity between candidate targets and known targets. However, in the case 
where a drug has no known target, (i.e. a new drug), computing target similarity is not possible. Hence, 
drug similarity must be used instead. In this case, potential targets of this new drug are selected based on 
target information for similar drugs for which target data is available. Semi-supervised learning methods 
can address the problem of predicting interactions for new drugs (or new targets).  
In addition to the previously mentioned methods, some drug repositioning methods leveraging drug-
drug similarity include refs [35], [36]. One of the main limitations of drug repositioning based on 
chemical structure similarity of drugs is that many structures and chemical properties of known drug 
compounds are inaccurate. Furthermore, many physiological effects of a drug cannot be predicted by 
structural properties alone [37].  
Computational assessment of similarities in molecular profiles is another approach for relating drugs 
to disease states for the purpose of repositioning [37], [38]. The role of molecular profile could be 
described as a signature of molecular activity after exposing a drug in a biological system. It may contain 
different measures such as a change in transcriptional activity. The similarity of these profiles could be 
used to establish useful relationships between drugs and diseases. There have been important methods of 
this type in the literature  [39], [40], [41].  
Many drugs induce some unintended effects in the living organism besides the primary desired effects, 
which constitute a drug’s overall effect profile. Those wanted or unwanted behavioral or physiological 
changes in response to drug treatment can be measured as a drug’s indication and side effects, 
respectively  [17], [42]. We know that side effects are generated when a drug binds to off-targets, which 
perturb unexpected metabolic or signaling pathways. These off-targets may, in fact, lead to the 
identification of novel therapeutic targets [7], [43]. So pharmacological information associated with drugs 
provides an alternative way to predict drug targets; this approach has proven to be complementary with 
the commonly used molecular information. Ye et al. [43] tried to reposition drugs by statistical analysis of 
                                                          
1
 There are manymetrics to measure the similarity between two drugs. For example, some are based on similarity of biological effects and some 
are based on similarity of chemical structures of drugs and so on. In this paper, special kinds of these similarities will be clarify explicitly 
whenever needed, and in general word “similarity of drug” could be referred to anysimilarity.  
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drug side effects. Zhang et al. [44] predicted adverse drug-drug interactions by integrating side effects 
with molecular information. The PREDICT [40] algorithm also used drug side effects to rank drug-
disease associations. 
There is some limitation for using of side-effect. First, the scarcity of drug adverse reaction 
information limits the application of this kind of approaches. In fact, side-effect-similarity approaches 
need a well-defined side effect profile for a drug while current disease and drug phenotype data are noisy 
and far from complete. Second, there is no side effect profile available for newly approved drugs [17], 
[7], [37]. Third, all drugs with similar effects do not possess similar targets necessarily.  Fourth, there is 
no simple mapping between phenotype and mechanism of action. The living organism’s genetic map, 
medication history, and other traits could effect on phenotypic outcomes of a drug. So, we could not 
conclude that a similar phenotype corresponds to the same mode of action [17], [7]. Finally, it should be 
noticed that side effect information could be confused by a patient’s medication history, genotype, and 
other hidden factors [17]. 
In drug repositioning, it is assumed that if molecular pathophysiology of therapeutic effects of two 
drugs has sufficient commonalities, they are interchangeable. [37]. So to reposition drugs, we require 
computational strategies for finding molecular relationships between distinct disease pathologies. This 
approach has been leveraged for DR in [42]. 
Previous studies indicate that integrative analysis, where multiple lines of evidence are considered 
simultaneously, is a practical approach to finding the most probable candidates for drug repositioning. 
Recently, some novel integrative methods have been proposed. Wang et al. [45] integrated three data 
sources from the structure, activity, and phenotype levels using a kernel function. Their PreDr method 
then uses an SVM-based predictor to uncover unknown interactions between drugs and diseases. 
However, the lack of high confidence known negative instances restricted its performance. They chose 
the known drug-disease pairs as the positives and randomly selected a set of training negatives from the 
unlabelled data. Many of these unlabeled data are, in fact, undiscovered drug-disease relationships; this 
leads to incorrectly labeled negative data and an important limitation that also applies to the other 
integrative approaches described below. 
Yamanishi et al. [46] developed a method to predict unknown drug–target interactions from chemical, 
genomic, and pharmacological data. This statistical method is based on supervised bipartite graph 
inference. Additionally, they investigated the topology of drug–target interactions networks. 
Wang et al. [47] proposed an integrative framework based on the information flow-based method, 
named TL_HGBI (Triple Layer Heterogeneous Graph Based Inference). The TL_HGBI tried to calculate 
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the weight2 of disease-drug relations by drug-target relationships using an iterative algorithm to combine 
heterogeneous information from different sources. 
In [1], Zhang et al. proposed a framework named  SLAMS (Similarity-based LArge-margin learning 
of Multiple Sources). SLAMS integrates different drug information, such as chemical properties 
(compound fingerprints), biological properties (protein targets), and phenotypic properties (side-effect 
profiles) to predict drug-target interaction.  
NRWRH [48] integrates three different networks (protein similarity network, drug similarity network, 
and the known drug–target interaction network) into a heterogeneous network. It then uses a random walk 
method for the prediction of drug–target associations. This methodology demonstrated good performance 
in predicting new interactions. However, random walking may lead to a locally optimal solution due to 
the sparseness of the drug–target interaction network. 
While integrative methods have been shown to outperform other approaches, these methods still face 
some common limitations outlined below: 
1) Most existing similarity-based prediction algorithms use only immediate similarities and don’t 
consider transitivity of similarity. To address this deficiency, Zhang et al. [44] proposed a label 
propagation approach that considers higher-order similarity which could be useful in drug 
repositioning research and help us in this regard.  
2) As mentioned above, in many methods negative drug-target interactions are selected randomly 
without experimental confirmation [33]. 
3) Interactions with new drugs (drugs without any known target) and new targets (targets without any 
known drug) cannot be predicted by some methods [49]. Semi-supervised learning methods could 
be useful in addressing this problem. 
4) Most existing methods are based on one or two kinds of data (like chemical structure similarity of 
drugs or sequence similarity of protein targets). On the other hand, existing training samples of 
established methods are very few when compared with all available unlabeled data.  
Our proposed method is a semi-supervised method without requiring negative training samples, and 
capable of utilizing information from unlabelled samples. Furthermore, it is applicable in the case of the 
new entity problem. Lastly, integration of different data types is used to improve the prediction accuracy. 
3 Method 
   We here design a novel algorithm to predict drug repositioning by associating known drugs with new 
diseases, different diseases with new targets, and drugs with new targets. 
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 confidence of the existence of the relationship 
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     This section will introduce the Heter-LP method, using drug repositioning as the illustrative example 
application. Subsection 3.1 presents the formal notations and settings used in the problem. Subsection 3.2 
covers data collection. Subsection 3.3 is about the projection step of the algorithm. Subsection 3.4 
explains the label propagation algorithm. Finally, in subsection 3.5, pseudo-code of the algorithm is 
presented.  
     The proposed data model consists of six parts, three homogeneous (1, 2, 3) and three heterogeneous (4, 
5, 6) sub-networks: (1) Drug similarity network, (2) Disease similarity network, (3) Target similarity 
network, (4) Known drug-disease associations, (5) Known drug–target interactions, (6) Known disease-
target associations. 
     A comprehensive description of using data for each part is represented in subsection 3.2. Our aim is to 
optimally integrate these different data sources and provide a ranked list of putative novel associations 
between drugs, diseases, and targets. Figure 1 is a schematic view of our heterogeneous network model 
and used datasets.  
3.1 Notations and problem settings 
Here we have three types of nodes: drugs, diseases, and targets. We have six different kinds of edges, 
each representing one type of similarity or association: drug similarity, disease similarity, target similarity 
network, known drug-disease associations, known drug–target interactions and known disease-target 
interactions.  
Therefore, we have a heterogeneous graph G = (V, E) with three homo-sub-networks and six hetero-
sub-networks (Figure 1). The homo-sub-networks are defined as Gi = (Vi, Ei) where i is 1, 2, 3 for drugs, 
diseases, and targets, respectively. The hetero-sub-networks are: Gi,j = (Vi⋃Vj, Ei,j) for i,j= 1, 2, 3. 
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Figure 1. Heterogeneous network model and used datasets 
Each Ei is the set of edges between vertices in the vertex set Vi of homo-sub-network Gi and each Ei,j ∈ 
Vi ×Vj is the set of edges connecting vertices in Vi and Vj.  
So in G,  V ={V1, V2, V3 } and E ={E1, E2,E3} ∪ { E1,2 , E1,3 ,E2,3}. 
    We represent the inputs of homo-subnetworks by one ni × ni affinity matrix3 Ai, where ni is the number 
of vertices in corresponding homo-subnetwork and Ai(k,k’) ≥ 0 is the similarity between entity k and k’. 
For example, the input drug network is represented by an |V1| × |V1| element square symmetric affinity 
matrix A1, where A1(k,k’) ≥ 0 is the similarity between drug k and k’. For each hetero-subnetwork, there is 
a relation matrix Ai,j with |Vi| rows and |Vj| columns. Each entry Ai,j(k,k’) €{0,1} reflects the absence or 
existence of a relation between entity k and entity k’, respectively. For example, the input drug-target 
network is represented by a |V1| × |V3| , binary matrix, named A1,3. A value of A1,3(k,k’)=1 indicates that 
there is a relation between drug k and target k’, whereas a value of  A1,3(k,k’)=0 indicates there is no 
relationship between drug k and target k’. All Ai and Ai,j matrices must be normalized (once at 
initialization) to ensure convergence of the updates, so that each row sum is one. We used the “LICORS” 
package [50] in R for this task and denoted the normalized matrices as Si and Si,j. 
In Figure 2, we try to clarify the process using the workflow. A brief description of each part and the 
data preparation methods are represented below. 
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 All homogenous sub-networks are affinities symmetric. 
Target
Drug
Disease
PubChem 
OMIM 
GO 
KEGG 
KEGG 
KEGG 
Preprint  5 Nov. 2016 
3.2 Data preparation 
In this section, we will study the characteristics of the datasets that are used in this research. Here we 
have three major concepts: disease, drug, and target. An intra-similarity matrix represents each concept, 
and three interaction matrices are describing the relation between each pair of these concepts. 
We used a gold standard dataset provided by Yamanishi (2008) [24] to provide the opportunity to 
compare prediction accuracy with previous methods more accurately. Additionally, we also gathered 
several independent datasets to provide a more realistic experimental analysis. Further details are 
provided below. 
3.2.1 Gold standard dataset 
   Yamanishi et al [24] provide a dataset contains drug, protein targets, and their interactions which are 
categorized by four groups of protein targets (Enzyme, GPCR, Ion Channel, and Nuclear Receptor).  The 
primary resources of these data are KEGG4, BRITE5, BRENDA6, SuperTarget7, and DrugBank8. The 
similarity-by structure of drugs is computed by SIMCOMP on chemical substructures, and similarity of 
targets is calculated by a normalized version of Smith-Waterman score. Some of the most important 
characteristics of these data are represented in Table 1 of supplementary materials. 
                                                          
4
 http://www.kegg.jp 
5
 http://www.genome.jp/kegg/brite.html 
6
 http://www.brenda-enzymes.org/ 
7
 http://insilico.charite.de/supertarget/ 
8
 http://www.drugbank.ca 
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DrugBank 
Sider 
OMIM 
Different 
datasets 
A heterogeneous 
network 
S1 
S1,2 
S1,3 
S2 
S2,1 S2,3 
S3 S3,1 
S3,2 
Bipartite network projection 
Mi= Laplacian normalize 
(Integration ( Wi, W’i, Si)) 
 i=1, 2, 3 
Wi , W’i     i=1, 2, 3   
 
Label Propagation  
(repeat 1, 2, 3 until convergence) 
1 
1 
1 
2 
2 
2 
3 
3 
3 
Primary outputs 
drugs 
01011
00001
00100
diseases 
010110
000100
100101
targets 
0101100
0010010
0101010 
drug_
diseas 
01011
00001
disease
_target 
010110
000100
drug_
target 
01011
00001
Final outputs 
drug disease priority 
Dr1 Di1 1 
Dr2 Di2 2 
…. …. …. 
disease target priority 
Di1 Ta1 1 
Di2 Ta2 2 
…. …. …. 
drug target priority 
Dr1 Ta1 1 
Dr2 Ta2 2 
…. …. …. 
Predicted drug-disease, disease-target, drug-target interactions 
drugs 
diseases 
targets 
A B 
C 
D 
E 
F 
G 
Figure 2 The overall process workflow for Heter-LP algorithm.  The alphabetic order could be used to find an 
appropriate understanding of the proposed method; (A) A schematic view of the datasets, explained in section 3.2 (B) 
The constructed network explained in section 3.1 and Fig. 1; (C) Our projection phase (equivalent to lines 2-7 in 
Algorithm section of represented pseudo code) explained in section 3.3.; (D) Equivalent to lines 8-10 in Algorithm 
section of represented pseudo code. In this part, we try to provide a laplacian normalization view of projection output. 
(E) The label propagation phase of the algorithm (equivalent to lines 11-13 in Algorithm section of represented pseudo 
code) explained in section 3.4. Arrows with label 1 are equivalent to line 11 and so on.  (F) Primary outputs are six 
matrices. Three of them are related to homo-sub-networks and three are related to hetro-sub-networks. Explanation is 
available in the end of section 3.5. (G) Final outputs are three sorted list of predicted interactions. Explanation is 
available in the end of section 3.5. 
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Though this dataset provides a useful benchmark for comparison of different methods, it has some 
limitations. In addition to being somewhat outdated, there is no information about associated diseases of 
drugs and targets in this dataset. Since the the concept of disease is a fundamental element in our model, 
we had to incorporate some extra data. For this purpose, we provided a list of related disease for each 
mentioned groups of gold standard datasets based on data provided by Li et al. [51] and DisGeNet [52], 
for drugs and targets respectively, and provide disease similarity from OMIM [53]. For example, we 
extracted all diseases related to drugs of Enzymes files of [24] from drug-disease lists of [51] in the form 
of a separate matrix and so on for other groups. Code written for this purpose is available upon request.  
3.2.2 Independent test datasets 
  In addition to the gold standard dataset, we also build an updated heterogeneous dataset gathered from a 
number of datasets representing the three key concepts used by the model (drug, disease, and target) and 
their inter-relations. A brief description of each dataset is provided below. 
Homogeneous sub-graphs 
G1.  Chemical substructures: It is believed that drugs with similar chemical structure carry out 
similar therapeutic function, thus, are likely treat common diseases [45]. 
In this experiment, the pairwise similarity of two drugs is calculated based on the 2D chemical 
fingerprint descriptor of each chemical structure in PubChem. That is, each drug d is represented by a 
binary fingerprint h(d) in which each bit represents a predefined chemical structure fragment. Each h(d) is 
an 881-dimensional chemical substructure vector defined in PubChem. These data were taken from [54]9, 
which contains 888 drugs and 881 substructures, and the description of the 881 chemical substructures is 
available at PubChem’s website. The pairwise chemical similarity between two drugs d1 and d2 is 
computed as the Tanimoto coefficient of their fingerprints using the “proxy” R package10.  
      Side effect similarities: Many drugs have adverse effects in addition to their indication, referred to as 
side effects. It has been shown that more accurate drug-target prediction can be achieved by integrating 
these side effects with other information, such as chemical similarities [7]. SIDER [55] is the primary 
resource for side effect data. We found 888 drugs and 1385 side effects in this online dataset. These data 
also represented drug-side-effect relationships using a fingerprint matrix (like one described in chemical 
structure similarity). The similarity of side effects between two drugs d1 and d2 is computed as the 
Tanimoto coefficient of their fingerprints using the “proxy” R package. This distance is integrated with 
the chemical structure similarity matrix using the arithmetic mean to produce the G1 sub-network. The 
                                                          
9
 http://cbio.ensmp.fr/yyamanishi/side-effect 
10
 https://cran.r-project.org/web/packages/proxy/index.html 
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combination of two drug-drug similarity matrices g1, g2 could be described by Eq. (1) below. Note that 
not all 888 drugs with structural fingerprint data had side effect information and vice-versa. 
	
	,  =  
, 
= 	,  + ,  2⁄ 													, 			
		2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,  3⁄ 																															, 												  
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G2. Semantic similarity of disease phenotypes: Text mining techniques were utilized to classify 
human phenotypes contained in the Online Mendelian Inheritance in Man (OMIM) database [53]. The 
phenotype similarity data are accessible through the website at http://www.cmbi.ru.nl/MimMiner/. A 
matrix of pairwise semantic similarity between diseases is available from their website which was 
constructed such that each entry is calculated based on the number of co-occurring MeSH (Medical 
Subject Headings) terms in the specialist descriptions of each disease pair from the OMIM database. In 
other words, each row (or column) is the phenotype similarity profile for a single disease. The number of 
diseases in this matrix is 4784.  
G3. Gene Ontology-based Sematic Similarity Measures: A drug target is a human protein, whose 
activity is modified by a drug, resulting in a desirable therapeutic effect [1]. Semantic similarity measures 
can be used to estimate the functional similarities among Gene Ontology terms and gene products. The 
pairwise semantic similarity protein pairs (drug targets) was computed using the “GOSemSim” package 
in R [56]. Here, we have 1537 protein targets.  
Heterogeneous sub-graphs 
Wu et al. [41] provided a useful list of relations between drugs, diseases, and protein targets extracted 
from KEGG. We divided these data into three separate lists of drug-disease, disease-target, and drug-
target relationships and then, by using the “reshape2” [57] R package, converted them into corresponding 
fingerprint matrices. So we have a  drug-disease matrix, G1,2, containing 584 drugs and 203 diseases with 
1041 relations between them; a drug-disease matrix, G1,3, containing 3592 drugs and 1504 targets with 
11610 relationships between them; and a  disease-target matrix, G2,3, containing 1087 diseases and 2255 
targets with 3296 relationships. The number of each type of entity in different sub-networks is shown in 
Table 2 of supplementary materials.  
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In the present work, drugs and diseases are referred to by name, while targets are referred to by KEGG 
ID. Conversion between IDs is accomplished using online tools like Synergizer11. 
3.3 Projection 
Bipartite networks have received considerable attention in the research community in different scientific 
areas. A bipartite network consists of two kinds of vertices (X, Y), and their edges are only allowed to 
connect to two vertices from different sets. Bipartite networks can model many different systems. To find 
a direct association between a particular set of vertices, we can compress them using “one-mode 
projection”. One-mode projection onto X results in a network containing only X vertices. In this newly 
generated network, two vertices are connected if they have at least one common neighbor in the primitive 
network. This projection can be weighted or unweighted; the weighted type is usually preferred. We will 
use a weighted one-mode projection technique based on the method represented by Zhou et.al [58].  
If A is an adjacency matrix between two vertex sets X and Y, we can project A onto X by Eq. (2): 
 =	 ! "
#$	"
 $% 
&
 &"
&
'
&(   (2) 
 
Here S is similarity matrix of vertex set X; K(x) is equal to the degree of vertex x in matrix A; and λ is 
diffusion parameter of the projection. If A is an n-by-m matrix, and S is n-by-n, the resulting matrix W 
will be n-by-n as well.  
As shown in Error! Reference source not found. and described in bipartite network projection section, 
we consider the primitive heterogeneous network as having three partitions. We apply our one-mode 
projection technique two times in each part separately. So we will have six different projection matrices. 
Each matrix can be used as a topological similarity matrix in the next section to improve the label 
propagation accuracy. We call them topological similarity matrices because of their ability to show 
different relations by weighted edges between one type vertices directly.  
 
3.4 Label propagation  
As noted in Section 1, we develop a heterogeneous label propagation algorithm to predict different 
types of the potential interactions in the network. In the naïve Label Propagation (LP) algorithm, there is 
an undirected weighted network with n nodes, of which are labeled, and the goal is to estimate the labels 
of the unlabeled nodes. Here, in each iteration, we have only one labeled node, and we attempt to predict 
the labels of others. In drug-drug homogeneous matrix the predicted labels would indicate similarities of 
                                                          
11 http://llama.mshri.on.ca/synergizer/translate/ 
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drugs, and in drug-target heterogeneous matrix the predicted labels would indicate the existence of an 
interaction between corresponding drug and target. 
The label propagation algorithm is closely related to the Random Walk (RW) algorithm. There are two 
major differences between LP and RW: (i) LP fixes the labeled points, and (ii) the solution of LP is an 
equilibrium state, while RW is dynamic. The LP algorithm is mathematically identical to Random Walk 
with Restart (RWR) algorithm if some constraints are applied to similarity matrix of RWR [32]. 
In this study, we require an algorithm to propagate label information across a heterogeneous network 
of drugs, targets, and diseases. A heterogeneous network is a network that consists of several sub-
networks of different types of vertices and edges. For instance, in a drug-target hetero-network, there are 
two kinds of nodes and three kinds of edges. Edges between two drugs and between two targets are 
weighted as an explanation of their similarity. The edges between a drug and a target are un-weighted 
edges which are here binary, indicating the presence or absence of a relationship between the drug and the 
target. Most graph-based label propagation algorithms propagate label information only on a single 
network or homogenous network, which are not suitable for spreading label information across 
heterogeneous networks. In this regard, Hwang et al. [59] proposed a heterogeneous label propagation 
algorithm, named MINProp. This method sequentially propagates the label on each sub-network. Another 
heterogeneous label propagation algorithm is LPMIHN [32], with the primary purpose of inferring 
potential drug–target interactions using a heterogeneous network. The LPMIHN algorithm propagates 
labels on each homogenous sub-network separately, and then the interactions between the two 
homogenous sub-networks are used only as extra information in the form of a similarity matrix. 
Here we apply label propagation on each sub-network using the existing information derived from the 
other sub-networks. The process repeats until convergence.  
In brief, the inputs of the proposed algorithm include the similarity matrices and interaction matrices. 
In each iteration, we aim to find the relations between each pair of entities using these inputs. We initially 
set the label of a particular entity to one and all others to zero. This label information is propagated 
through the entire network to determine the relationship between the investigated entity and all others as 
newly assigned labels emerge. These new labels are saved in three vectors and, before the next iteration, 
are saved in specific matrices. Finally, we sort these output matrices from largest to smallest value of 
achieved label and determine the most important relations as the top scoring elements in each matrix.   
3.5 Implementation 
To clarify details of the proposed method, the pseudo code of our Heter-LP algorithm is presented 
below as Algorithm1. 
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Algorithm 1  Heter-LP  
Input 
1) σ: total convergence threshold 
2) σ’: homogenous convergence threshold 
3) α: diffusion parameter of label propagation 
4) λ: diffusion parameter of projection 
5) y1, y2, y3: vectors of initial label values 
6) S1, S2, S3: homo-subnetwork matrices 
7) S1,2 , S1,3 , S2,3: hetero-subnetwork matrices 
8) drugs list (n1 is the number of total drugs) 
9) diseases list (n2 is the number of total diseases) 
10) targets list (n3 is the number of total targets) 
 
Output 
1) F1, F2, F3: homo-subnetwork matrices of final label values 
2) F1,2 , F1,3 , F2,3 : hetero-subnetwork matrices of final label values 
 
Algorithm 
1. Fk=0, Fk,k’=0 for all k,k’=1,2,3 
//Projection 
2. W1n1*n1 = projection of S1,2 on S1 
3. W’1n1*n1 = projection of S1,3 on S1 
4. W2n2*n2 = projection of S1,2 on S2 
5. W’2n2*n2 = projection of S2,3 on S2 
6. W3n3*n3 = projection of S1,3 on S3 
7.   W’3n3*n3 = projection of S2,3 on S3 
   //Integration of similarity matrix with projected matrices 
8. M1=NormalizeSumOf(S1,W1,W’1) 
9. M2=NormalizeSumOf(S2,W2,W’2) 
10. M3=NormalizeSumOf(S3,W3,W’3) 
   // label propagation 
11. for i=1.. y1.length 
11.1) y1[i]=1 , y1[j]=0  for all j≠i 
11.2) y2=y3=0 
11.3) f1=y1, f2=y2, f3=y3  // vectors of final label values 
11.4) LabelPropagation(f1,f2,f3) 
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11.5) update F1 , F1,2 , F1,3 
12. for i=1.. y2.length 
12.1) y2[i]=1 , y2[j]=0  for all j≠i 
12.2) y1=y3=0 
12.3) f1=y1, f2=y2, f3=y3   
12.4) LabelPropagation(f1, f2, f3) 
12.5) update F2, F2,1 , F2,3 
13. for i=1.. y3.length 
13.1) y3[i]=1 , y3[j]=0  for all j≠i 
13.2) y1=y2=0 
13.3) f1=y1, f2=y2, f3=y3  // vectors of final label values 
13.4) LabelPropagation(f1, f2, f3) 
13.5) update F3, F3,1  , F3,2 
 
14. F1,2=mean (F1,2 , transpose(F2,1)) 
15. F1,3=mean (F1,3 , transpose(F3,1)) 
16. F2,3=mean (F2,3 , transpose(F3,2)) 
17. return F1, F2 , F3, F1,2 , F1,3 , F2,3  
       NormalizeSumOf(S,W,W’) 
1. d=0 //a vector with  S.numberOfRows length 
2. for i=1..S.numberOfRows 
2.1. for j=1..S.numberOfColumns 
2.1.1. M[i,j]=S[i,j]+W[i,j]+W’[i,j] 
2.1.2. d[i]=d[i]+M[i,j]   
       2.2 if (d[i]==0) d[i]=1 
3. for i=1..M.numberOfRows 
3.1. for j=1..M.numberOfColumns 
3.1.1. if (i==j) M[i,j]=1 
3.1.2 else if (	i! = j	,-.	M0i, j1! = 0 M[i,j]=	 304,51670417051 
3.1.3 else M[i,j]=0 
4. return (M) 
LabelPropagation(f1, f2, f3) 
1. repeat (steps 2-11) 
  //drug 
2.  f1old = f1 
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3.       y’1 = (1-α1)f1 + α1(S1,2*f2 + S1,3*f3) //f1 is equal to y1 
4.       f1 = (1-α1)y’1 + α1*M1*f1 
  //disease 
5.  f2old = f2 
6.       y’2 = (1-α2)f2 + α2((S1,2)T*f1 + S2,3*f3)  //f2 is equal to y2 
7.       f2 = (1-α2)y’2 + α2*M2*f2 
  //target 
8.  f3old = f3 
9.        y’3 = (1-α3)f3+α3((S1,3)T*f1 + (S2,3)T*f2)  //f3 is equal to y3 
10.      f3 = (1-α3)y’3 + α3*M3*f3 
11.  while (||f1-f1old||>σ or ||f2-f2old||>σ or ||f3-f3old||>σ ) 
 
 
 
In Algorithm 1, first, we set all labels to zero. During the projection phase, we project interactions onto 
similarity matrices by equation (2). We will have six projected matrices which will be integrated with 
corresponding similarity matrices in lines 8-10. In label propagation phase we have three iterative loops 
(lines 11-13). In each loop, we set one of the original labels equal to one and all others to zero. The label 
propagation function is applied, and output matrices are updated. The primary output consists of nine 
matrices; two of them correspond to drug-target interaction, two others correspond to drug-disease 
associations, two others are correspond to disease-target associations. Three remaining are drug-drug, 
disease-disease and target-target relations as separate matrices. We convert these nine matrices to six by 
merging of matrices related to similar concept (for example two drug-target interaction matrices are 
merged to produce one matrix and similarly for others). Final interaction prediction is achieved by sorting 
the rows of these matrices.  
Algorithm 1 is implemented in C# using Visual Studio 2013 (the source code is available upon request 
from the author).  
3.6 Key points in Heter-LP 
The main idea of our projection phase is extracted from [60] and [61]. DT-Hybrid algorithm [22] which is 
one of the best approaches for prediction of drug-target interactions, is also a recommendation method 
based on projection. DT-Hybrid attempts to provide a similarity matrix for a set of vertices (like Y) by 
using the similarity between other sets of vertices of the corresponding bipartite network (like X) across 
their relations. However, here we focus on relationships between two sets and try to extract a topological 
similarity matrix by it. In this way we reduce the required computational tasks in comparison to DT-
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Hybrid. Moreover, we use the similarity matrix of set X at label propagation phase. In this way, the 
similarity effects of vertices are not only through direct links but also we provide a kind of transitivity. 
In label propagation phase, although there are some similarities with MINProp algorithm [59] there are 
several notable advantages. First, we use integrated data from primiary input data and output of the 
projection phase as input for label propagation section. Second, there is one less iterative loop here which 
reduce the computational complexity of the algorithm impressively. It is noticeable that other 
heterogeneous label propagation algorithms like LPMIHN [32] also could not reduce the iterative loops in 
this way. 
Moreover, Heter-LP has some more general advantages which include:  
• No need to any inadvisable preprocessing of data. In other heterogeneous label propagation 
algorithms, it is assumed that there is coincidence between one homogenous set of vertices with 
equivalent vertices in heterogeneous networks. To provide it, they had to remove some 
informative data in the preprocessing phase. Heter-LP does not need to such a preprocessing 
because of no need to such a coincidence. 
• No need to know the negative samples. Here negative samples mean interactions which could not 
exist biologically. Most of other drug repositioning methods need to know negative samples and 
try to provide them randomly (there is no category for negative samples in this field). 
• Heter-LP can predict interactions of new drugs (where a drug has no known target) and new 
targets (where a target has no known drug). This property is considered only in a few other 
methods. 
• The other benefit of the proposed method is its ability to predict both trivial and non-trivial 
interactions. Trivial means the interactions which are predictable at first glance by everyone 
because of the existing similarities. Non-trivial interactions are the interactions that more 
evidence is required to find them. 
4 Convergence Augment 
An important part of the proposed method is the “LabelPropagation(f1, f2, f3)” function. This 
function is based on an iterative algorithm whose convergence is here demonstrated. In fact, we will show 
that the sequences {f1(t)}, {f2(t)},and {f3(t)} will ultimately converge and their corresponding answers are: 
∗ = 9 − ;<#01 − ; + 1 − ;>;!, + 1 − ;>;!,>>1 
∗ = 9 − ;<#01 − ; + 1 − ;>;!, + 1 − ;>;!,>>1  (3) 
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>∗ = 	 9 − ;<>#01 − ;> + 1 − ;>;!>, + 1 − ;>;!>,1 
Without loss of generality, we consider the same α for all sub-networks and rewrite (1-α) as β. So our first 
iterative equations will be as below: 
 = ?? + ;!, − 1 + ;!,>> − 1 + ;< − 1  = ?? + ;!, + ;!,>> − 1 + ;< − 1 > = ??> + ;!>, + ;!>, + ;<>> − 1	
 
 (4) 
By substitution of the above, we find: 
 = 	 @?%;<A#(B  +	;<A	C
+	@?>;%;<A#(B !,	 +	?;;<A#!,	C
+	0?>;%;<A#(B !,>	> + ?;;<A#!,>>1 +	D			
 = 	?%;<A(B  +	?>;%;<
A#
(B !,	 + ?>;%;<
A#
(B !,>	> + D	
> = 	?%;<>A(B > +	?>;%;<>
A#
(B !>,	 + ?>;%;<>
A#
(B !>,	 + D>	
 
 (5) 
Where, each Pi is a summation of different t power of ! and !,  and they will converge to zero as 
iterations progress. 
The final results will be achieved by  EFA→H   which are: 
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f∗ = limA→H = limA→H @?%;<
A#
(B  +	;<A	C
+ limA→H @?>;%;<
A#
(B !,	 +	?;;<A#!,	C 	
+ limA→H @?>;%;<
A#
(B !,>	> +?;;<A#!,>>C + limA→HD
≅ limA→H @?%;<
A
(B C + limA→H @?>;%;<
A#
(B !,	C 	
+ limA→H @?>;%;<
A#
(B !,>	>C + limA→HD	 
 (6) 
	
We know that: 
limA→H @?%;<
A
(B 	C = ?9 − ;<#		
limA→H @?>;%;<
A#
(B !,	C = 	?>;9 − ;<#!,	
limA→H @?>;%;<
A#
(B !,>	>C = ?>;9 − ;<#!,>	>	limA→HD = 	0 
 
 (7) 
So the final equation for ∗ will be: 
∗= limA→H 	 = 	 1 − ;9 − ;<# + 1 − ;>;9 − ;<#!, +1 − ;>;9 − ;<#!,>> =	 9 − ;<#01 − ; + 1 − ;>;!, +1 − ;>;!,>>1 
 
 (8) 
In the same way for ∗ and  >∗, we can write: 
∗= limA→H  = 	 1 − ;9 − ;<# + 1 − ;>;9 − ;<#!,+ 1 − ;>;9 − ;<#!,>>= 9 − ;<#01 − ; + 1 − ;>;!, + 1 − ;>;!,>>1 
 (9) 
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>∗= limA→H >	 = 	 1 − ;9 − ;<>#> + 1 − ;>;9 − ;<>#!>,+ 1 − ;>;9 − ;<#!>,=	 9 − ;<>#01 − ;> + 1 − ;>;!>,+ 1 − ;>;!>,1 
 
We express the resulting equation in closed-form as Eq. (10) below: 
∗ = 9 − ;<#01 − ; + 1 − ;>;∑ !,  	1 N   for i,j	=	1,2,3	  (10) 
 
Here we have three homogeneous sub-networks. It can be easily verified that if we set i,j	=	1,2,…,	k	,	then 
Eq. (10) will be correct for a heterogeneous network with k different homogenous sub-networks. 
Now we must choose a value for the constant parameter α. It seems that α cannot be arbitrarily large. If 
we let α→0, then all final labels will be equal to the initial ones. If we increase α from zero, we will come 
to a point at which 9 − ;<# will diverges and cause the divergence of fi. This will be happen when 
the determinant of 9 − ;< passes through zero [62]. We can rewrite this condition as < −;#9 = 0. This will be happen when the roots of ;# are equal to the eigenvalues of <. When ;# 
becomes equal to the largest eigenvalue (ki) of <, the determinant first crosses zero. Therefore, we must 
choose a value of α less than 1/ki.   
    The final labels can be calculated directly from Eq. (10). However, this would require the inversion of 9 − ;<. In order to invert this n*n matrix, a time proportional to O(n3) is required by matrix 
multiplication algorithms, which can at best be reduced to O(n2.373) through algorithmic optimization12. 
Therefore, we instead prefer to use the direct equations represented in Eq. (4). By repeating the process 
several times, the results will converge to the correct values.  
We here measure the required runtime for each step (projection and label propagation) separately. In the 
projection phase, we need to know the degrees of all the vertices of the interaction matrix. The required 
time is Q	2R|T|UT UV. The expected time to project one interaction matrix on one similarity matrix is QR	|T|UT UV	which is repeated six times. So the total runtime for projection phase is Q6		2R|T|UT U +	|T|UT UV. 
                                                          
12 https://en.wikipedia.org/wiki/Computational_complexity_of_mathematical_operations 
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For label propagation on each homogeneous sub-network, the required time is equal to Q		R|T| +	∑ |T|UT U N +	|T|V and the total runtime of label propagation phase will be:  
Q		 ∑ R|T| + 	∑ |T|UT U N +	|T|V>(   
The total time for calculation is proportional to t, where t is the number of iterations required to reach 
convergence. The value of t depends on the input data structures and the parameter α. Therefore, we 
cannot determine the necessary time independently on the runtime parameters. However, in our 
experiments, α was always smaller than and equal to 0.3 and the value of t was always smaller than 10.  
5 Regularization Framework  
Here we develop a regularization framework for the proposed label propagation algorithm. First, an 
objective function is determined. Then we will show that this function is strictly convex and will therefore 
have a globally optimal solution. We describe this solution and find it equal to the results of the previous 
section. In this way, it is proved that our proposed method will find an optimal solution. 
The objective function: A a cost function is defined to propagate a label in a heterogeneous network G 
(V, E), as Eq. (11) below: 
Ω = 	%YZ∆ + \‖ − ‖ +	\%%^Z Z_% ` a, 	
>
 (

( b
>
(  	
 (11) 
where  
•  ∈ c|d| is label vector, 
•  is the initial label vector 
• ∆= 9 −	<   
• ∑ = 9 − e 0 !, !, Z 0 f, 	  is the normalized graph laplacian of !,  
• and ||.|| indicates a vector norm. 
Ω consists of three cost terms:  
• Z∆ is a smoothness term on the homogenous sub-network g = RT, hV which causes the 
similarity of labels of the connected nodes in the network g. 
• ‖ − ‖ is a fitting term which tends to keep the new label values near to the initial ones. 
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• 0Z Z1∑ ` a, 	  is a smoothness term on the heterogeneous sub-network g,  = RTj	T , h, V 
which ensures the similarity of labels of connected nodes in the network g, . 
Proposition 1: Ω	 is strictly convex. 
Proof: All of ∆ and ∑ 	, 	 terms are graph laplacian. This means that they are positive semi-definite and 
cause the convexity of the first and third cost terms of Ω. The second cost term is also convex. All of 
them are multiplied by some positive constants. So  Ω is a nonnegative-weighted sum of some convex 
function and is therefore itself a convex function [63]. 
On the other hand, the Hessian matrix of Ω is a summation of	∆, ∑ 	, 	  and I. The ∆  and  ∑ 	, 	 terms 
 are positive semi-definite and I is positive definite, so the Hessian matrix of Ω	is positive definite13. 
Therefore, Ω is strictly convex.■ 
Proposition 2: The optimal solution of Ω  is: 
∗ = 9 − ;1<#0;2 + ;3%!,  1 N   (12) 
Proof: As proven in Proposition 1, Ω  is strictly convex, so it can be solved by alternating optimization 
[63]. For each	, all    terms for 	 ∈ k	|	 ∈ ℕ, 1 ≤  ≤ 3	,  ≠ } are considered constant. We can then 
differentiate Ω with respect to fi and set it equal to zero to compute the solution: 
Ω  = 0 
∗ −<∗ + 2μ∗ −  + 2∗ −%μ!,   N = 0 
 
 (13) 
We will have: 
3 + 2\9 −	<∗ − 	2μ −	%μ!,   N = 0 
∗ = q9 − <3 + 2\r
#  2\3 + 2\  + \3 + 2\%!,   N  
 (14) 
                                                          
13
 If ∇ ≻ 0 for all x∈ domain(f), then f is strictly convex 63 Boyd, S., and Vandenberghe, L.: ‘Convex Optimization’ (Cambridge 
University Press, 2004. 2004). 
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We will set: 
;1 =	 >uvw , ;2 =	 vw>uvw, ;3 = 	 vw>uvw  (15) 
So the closed form of the solution will be: 
∗ = 9 − ;1< 	#0;2 +	;3 ∑ !,  	 N 1■ (16) 
 
Proposition 3: The proposed algorithm will minimize the objective function Ω. 
Proof: We should show that the result of Proposition 2 is equal with our answer in Eq. (10).  
We could rewrite the iterative Eq. (3) as: 
 = 	 1 − ; + ;< − 1 +% 1 − ;;!,   − 1 N  
i, j= 1,2,3 	
 (17) 
This is the equation solved by our proposed method and the result is: 
∗ = 9 − ;<#01 − ; + 1 − ;>;%!,  	1 N   (18) 
 
If we set: ;1 = 	;	 , ;2 =	 1 − ;,  ;3 = 1 − ;>; 
Both Eq. (16) and Eq. (18) will be equal.■  
So we have an optimization problem with the objective function represented by Eq. (11) which is strictly 
convex and, therefore, the proposed method can find its global minimum. 
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6 Performance evaluation 
In this section, we report on the results of our experiments to evaluate the performance of the proposed 
algorithm using the datasets described in Section 3. 
6.1 Statistical analysis 
We considered three different scores as indicators for prediction accuracy:  
1. Area Under the Curve (AUC) of the Receiver Operating Characteristics (ROC) curve 
2. Area Under the Precision-Recall (AUPR) curve 
3. BestAccuracy 
ROC is the plot of true positive rate (TPR) as a function of false positive rate (FPR) evaluated at 
various decision thresholds, where the true positives are correctly predicted true interactions and the false 
positives are predicted interactions not present in the gold standard set of interactions.  
Precision is defined as the fraction of true drug targets identified among the candidate proteins ranked 
above the particular decision threshold. Recall is the fraction of true drug targets identified from among 
the total number of true drug targets in the gold standard set of interactions. 
Although AUC represents the overall performance of the algorithm, previous studies have demonstrated 
that precision-recall curves more accurately assess a method’s performance in the face of skewed node 
degree distributions in scale-free biological networks [9]. Precision-recall (PR) curves are also more 
informative when significant class imbalance exists. Furthermore, a curve dominates in ROC space if and 
only if it also dominates in PR space [35].  
Accuracy measures the difference between a measurement with the actual value. It could be defined as 
equation (19): 
accuracy=
TP+TN
TP+FP+TN+FN
 
 (19) 
 
Here, TP = True Positives, FP = False Positives, TN = True Negatives, and FN = False Negatives.  
The highest achieved accuracy repeated experiments with the same parameter values over the same 
data is defined as “BestAccuarcy”. 
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6.1.1 Results based on gold standard dataset 
We performed 10-fold cross-validation (10-CV) to analyze the performance of the proposed Heter-LP 
method. In a 10-CV experiment, we split the dataset into ten subsets of equal size; each subset is then 
taken in turn as a test set, and the training is performed on the remaining nine sets.  
Table 1 shows the results of the proposed method during 10-CV over the gold standard datasets of 
Yamanishi 2008 [24] with augmented information as described in section 3.2.1. One can observe that the 
results of drug-target prediction are the strongest. This indicates that Heter-LP can predict drug-target 
interactions more accurately than the other two interactions. We repeated this test using some other 
methods and observed the same trend. This result appears to be due to incompleteness of the input data. 
As explained before, the available golden standard dataset doesn’t contain any information about diseases 
and our attempt for the addition of such information was insufficient to create a suitable complete dataset. 
In other words, the disease similarity matrix and the primitive interaction matrices used here are not 
sufficiently informative.  
6.1.2 Comparison with state of the art methods on gold standard data 
To provide the opportunity to compare the performance of different methods, two-column charts are 
represented in Figure 3 and Figure 4. Represented performances are self-reported by the corresponding 
papers (more explanation is represented in supplementary material). The corresponding numerical values 
are available in Table 3 of supplementary materials. We found that “DT-Hybrid” performs best. So we 
downloaded this package and evaluated it for two reasons. Firstly, to analyze two other types of 
interactions mentioned before (disease-target, drug-disease) and secondly, to find the accurate 
performance of this package with 10-CV. 
6.1.3 Comparison of 10-fold CV results 
In total, DT-Hybrid’s results are weaker than our proposed method in disease-target and drug-disease 
prediction. The results are presented in Table 2 and Table 3. It is difficult to determine which method is 
best overall; in 8 of 12 cases Heter-LP is the top-performing methods while in 4 of 12 cases, DT-Hybrid 
is the best. 
We also implemented an example of a poorly performing method, MINProp [59], and evaluated it 
using the gold standard data. The 10-CV results are represented in Table 2 and Table 3. As you can see, 
they are substantially weaker than the two other methods.  
Table 1 Results of Heter-LP method during 10-CV testing on the gold standard dataset 
Interact
ion 
Dataset: E Dataset: GPCR Dataset: IC Dataset: NR 
AUC AUP Best AUC AUP Best AUC AUP Best AUC AUP Best 
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R Acc R Acc R Acc R Acc 
Drug- 
Disease 
0.8292 0.8475 0.7231 0.8606 0.8697 0.7468 0.8400 0.8539 0.7340 0.8640 0.8625 0.7582 
Drug-
Target 
0.9918 0.4967 0.9917 0.9928 0.8575 0.9873 0.9878 0.7684 0.9856 0.9823 0.8965 0.9789 
Disease-
Target 
0.9147 0.8020 0.9449 0.8529 0.7381 0.8850 0.9163 0.8096 0.9454 0.9383 0.9459 0.9444 
 
 
Figure 3 Self-reported AUC  of various methods in gold standard datasets. 
 
 
Figure 4 Self-reported AUPR of some different methods in gold standard datasets. 
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Table 2 Results of 10-fold cross validation on E & GPCR datasets. 
Method Interaction Dataset: E Dataset: GPCR 
AUC AUPR BestACC AUC AUPR BestACC 
 
DT-Hybrid (R) Drug-disease 0.715656 0.736074 0.695336 0.695598 0.713113 0.667188 
Drug-target 0.947071 0.824319 0.996805 0.937225 0.829404 0.987817 
Disease-target 0.637279 0.641289 0.612389 0.668512 0.682871 0.636683 
 
Heter-LP 
 
Drug-disease 0.77056 0.81442 0.70544 0.79321 0.83176 0.72315 
Drug-target 0.95262 0.41505 0.99142 0.96747 0.79579 0.98584 
Disease-target 0.84988 0.75554 0.88614 0.79582 0.69718 0.84017 
 
MINProp  Drug-disease 0.4776 0.4745 0.5039 0.5 0.2479 0.5043 
Drug-target 0.5108 0.0119 0.9901 0.4978 0.0239 0.9700 
Disease-target 0.5195 0.5122 0.5222 0.5014 0.5326 0.5033 
 
Table 3 Results of 10-fold cross validation on IC & NR datasets. 
Method Interaction Dataset: IC Dataset: NR 
AUC AUPR BestACC AUC AUPR BestACC 
 
DT-Hybrid (R) Drug-disease 0.673724 0.707504 0.641833 0.689028 0.698906 0.661216 
Drug-target 0.923267 0.764408 0.983021 0.947913 0.903397 0.987536 
Disease-target 0.648534 0.655571 0.627719 0.757061 0.771653 0.725762 
 
Heter-LP 
 
Drug-disease 0.77764 0.81822 0.71237 0.80473 0.82928 0.73516 
Drug-target 0.94828 0.71143 0.98364 0.94797 0.83816 0.97523 
Disease-target 0.85669 0.77125 0.89916 0.88147 0.90672 0.89813 
 
MINProp Drug-disease 0.5 0.2497 0.5005 0.5 0.2470 0.5059 
Drug-target 0.5 0.0172 0.9655 0.5229 0.0679 0.9359 
Disease-target 0.5 0.2498 0.5004 0.4928 0.4726 0.5145 
 
6.1.4 Prediction of a deleted interaction 
A standard approach for validating a method is to remove some of the desirable entries from the input, 
then to run the process and finding the results (as one does during a cross-validation experiment). In this 
regard, we performed two distinct examinations. We chose an arbitrary drug (or target) and, as Test1, we 
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deleted one of its interactions from the input dataset and, as Test2, we deleted all of its interactions with 
targets (or drugs) from the dataset. Test1 is explained here and Test2 will be described in the next section. 
By deleting a single interaction, we investigate the ability of the method in predicting new interactions 
for known drugs or targets (i.e. nodes that have some known interaction with others). We perform 
different analysis tasks in this regard, and here we illustrate a case study. D00232 is a drug with three 
interaction with targets: hsa:1128, hsa:1129 and hsa:1131. We deleted its interaction with hsa:1129 from 
the input network and investigated the results. Both Heter-LP and DT-Hybrid correctly predict this 
removed interaction, as can be seen in Table 4. This list also contains several high scoring novel drug-
target predictions which merit experimental validation.  
 
Table 4 Top 20 predicted targets of Drug: D00232 by proposed method 
NO. Heter-LP DT-Hybrid 
1 hsa:1128 hsa:1128 
2 hsa:1131 hsa:1131 
3 hsa:1129 hsa:1129 
4 hsa:11255 hsa:1132 
5 hsa:154 hsa:3269 
6 hsa:3269 hsa:1133 
7 hsa:153 hsa:3360 
8 hsa:1813 hsa:8843 
9 hsa:148 hsa:1813 
10 hsa:4988 hsa:3356 
11 hsa:185 hsa:148 
12 hsa:150 hsa:3358 
13 hsa:3577 hsa:1812 
14 hsa:3274 hsa:1815 
15 hsa:152 hsa:146 
16 hsa:147 hsa:147 
17 hsa:3360 hsa:59340 
18 hsa:146 hsa:11255 
19 hsa:1814 hsa:150 
20 hsa:155 hsa:151 
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6.1.5 Prediction of pseudo-new drugs 
As mentioned above, our method can predict the interactions between new targets and new drugs 
correctly. This feature offers a great advantage that most of the existing methods do not provide. In this 
regard, we perform Test2 to create a pseudo-new drug and compare the results of our proposed method 
with DT-Hybrid. 
In the previous section, we explained that drug D00232 has three targets in the gold standard drug-
target interaction. We first deleted all of these interactions. In this way, D00232 is like a new drug in that 
it no longer has any known interactions with any target in the input network. Both Heter-LP and DT-
Hybrid were then applied to the censored dataset. The top 20 targets predicted by Heter-LP are presented 
in Table 5. All of the desired targets (which we deleted from the input data) are predicted successfully by 
our method (see bold entries in Table 5). Recall that these were recovered from among 989 possible 
targets. However, DT-Hybrid could not predict any target for this new drug (all of the entries of D00232 
in its output were zero). 
Similar examinations were conducted for some other drugs (like D05353, D00227) and for a variety of 
creating pseudo-new targets by removing all known interactions with drugs. Results were largely 
consistent with those of Test2, but results are excluded due to space limitation. 
Table 5 Top 20 predicted targets of Drug: D00232 by proposed method 
NO. Predicted target 
1 hsa:154 
2 hsa:3269 
3 hsa:153 
4 hsa:1128 
5 hsa:1813 
6 hsa:148 
7 hsa:4988 
8 hsa:185 
9 hsa:1129 
10 hsa:3577 
11 hsa:150 
12 hsa:3274 
13 hsa:1814 
14 hsa:146 
15 hsa:3360 
16 hsa:1131 
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17 hsa:3356 
18 hsa:147 
19 hsa:155 
20 hsa:151 
 
6.2 Experimental analysis 
Statistical analysis confirms the ability of the proposed method in predicting potential interactions, now is 
the time to investigate its practical effectiveness. In this regard, we used all the data as training set and 
examined new predicted interactions. Then we rank the unknown interactions on their scores and extract 
the top 20 predictions. These novel interactions were checked manually using the online version of 
DrugBank14, Supertarget15, KEGG Drug16 and Therapeutic Target Database (TTD)17. 
This test is performed two times, one based on the gold standard dataset and the other one using the 
introduced independent datasets (Section 3.2.2). Because of space limitations, the full predicted lists are 
placed in supplementary materials. 
We categorized the predictions in two groups, trivial and non-trivial ones. Trivial predictions could be 
predicted by straightforward and primary investigations of the input data. Non-trivial could not be quickly 
discovered from input data. It seems that an effective method should be able to identify both types 
sufficiently. Some examples are represented in the following sections.  
6.2.1 Experimental analysis based on gold standard dataset 
We sorted the predicted list of unknown drug-target interactions of each group (E, GPCR, IC, NR) and 
extracted the top 20 ones of each group separately. Because of space limitations, only the results of GPCR 
are represented here in Table 6; others are available in Tables 4-6 of supplementary materials. A similar 
investigation was done by some of the other methods like BLM [30], KBMF2k [23], LapRLS [33], 
LPMIHN [32], NetCBP [28], NRWRH [48], RLS-Kron18 [30], WNN [31]. Table 7 of supplementary 
materials is a brief comparison of the results of experimental analysis of different methods. 
Verified predictions in Table 6 are denoted by the name of the related source. As you can see, seven of 
20 GPCR interactions are verified. Furthermore, a number of the non-validated predictions have 
additional supporting  biological evidence that are out the scope of this paper. One non-trivial example 
prediction is discussed in the following case study. 
                                                          
14
 http://www.drugbank.ca/ 
15
 http://insilico.charite.de/supertarget/ 
16
 http://www.genome.jp/kegg/drug/ 
17
 http://bidd.nus.edu.sg/group/cjttd/ 
18
 Regularized Least Squares (RLS) with Kronecker sum kernel 
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Table 6 The top 20 new predicted interactions in GPCR dataset 
NO. pair Annotation  Verification 
source Drug Target Drug Target UniprotName 
of target 
1 D00542 hsa:338442 Halothane 
(JP17/USP/INN) 
G-protein coupled 
receptor 109A 
NIAR1_HUMAN   
2 D02358 hsa:154 Metoprolol 
(USAN/INN) 
Beta-2 adrenergic 
receptor 
ADRB2_HUMAN  SuperTarget 
3 D04625 hsa:154 Isoetharine (USP) 
Isoetarine (INN) 
Beta-2 adrenergic 
receptor 
ADRB2_HUMAN  KEGG 
4 D02614 hsa:154 Denopamine 
(JAN/INN) 
Beta-2 adrenergic 
receptor 
ADRB2_HUMAN   
5 D02147 hsa:153 Albuterol (USP) 
Salbutamol 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN  SuperTarget 
6 D02359 hsa:153 Ritodrine 
(USAN/INN) 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN   
7 D00683 hsa:153 Albuterol sulfate 
(USP) 
Salbutamol sulfate 
(JP17) 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN  SuperTarget 
8 D05792 hsa:153 Salmeterol 
(USAN/INN) 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN   
9 D00688 hsa:153 Terbutaline sulfate 
(JP17/USP) 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN  SuperTarget 
10 D00684 hsa:153 Bitolterol 
mesylate (USAN) 
Bitolterol mesilate 
(JAN) 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN   
11 D01386 hsa:153 Ephedrine 
hydrochloride 
(JP17/USP) 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN  KEGG 
12 D00687 hsa:153 Salmeterol 
xinafoate 
(JAN/USAN) 
Beta-1 adrenergic 
receptor 
ADRB1_HUMAN  SuperTarget 
13 D00673 hsa:3269 Ranitidine 
hydrochloride 
(JP17/USP) 
Histamine H1 
receptor 
HRH1_HUMAN  
14 D03503 hsa:3269 Cimetidine 
hydrochloride 
(USP) 
Histamine H1 
receptor 
HRH1_HUMAN  
15 D00422 hsa:3269 Ranitidine 
(USAN/INN) 
Histamine H1 
receptor 
HRH1_HUMAN  
16 D00440 hsa:3269 Nizatidine 
(JP17/USP/INN) 
Histamine H1 
receptor 
HRH1_HUMAN  
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17 D00295 hsa:3269 Cimetidine 
(JP17/USP/INN) 
Histamine H1 
receptor 
HRH1_HUMAN  
18 D00765 hsa:1128 Rocuronium 
bromide 
(JAN/USAN/INN) 
Muscarinic 
acetylcholine 
receptor M1 
ACM1_HUMAN  
19 D01346 hsa:3269 Bentiromide 
(JAN/USAN/INN) 
Histamine H1 
receptor 
HRH1_HUMAN  
20 D00760 hsa:1128 Doxacurium 
chloride 
(USAN/INN) 
Rocuronium 
bromide 
(JAN/USAN/INN) 
Muscarinic 
acetylcholine 
receptor M1 
 
  
Although we also had predicted drug-disease and disease-target interactions, we do not discuss them 
here since none of the compared methods are capable of making such predictions. Instead, these 
interactions will be discussed in the experimental analysis based on independent datasets. 
On the other hand, we claim that our proposed method could predict trivial and non-trivial 
interactions. Here we will explain two case studies to demonstrate this claim. 
A trivial case study:  (D02358 & hsa:154) 
D02358 is the KEGG id of drug Metoprolol (USAN/INN) and hsa:154 is the KEGG id of protein 
target Beta-2 adrenergic receptor which is also known by its UniProt name ADRB2_HUMAN. No 
interaction is defined between D02358 and hsa:154 in our using gold standard dataset as input (the 
corresponding entry in G1,3 is zero). 
We searched the SuperTarget website in August 2016 and find hsa:154 as a target of D02358. We 
therefore consider this to be a trivial prediction since it could have been predicted via simple research. 
According to the input similarity matrix of protein targets, hsa:154 is the most similar target to hsa:153. 
However, according to our input interaction matrix, hsa:153 is the sole target of D02358. It is reasonable 
to introduce the pair (D02358 & hsa:154) as one the most probable candidates (row 2 of Table 4) and new 
experimental research (listed in SuperTarget) indeed verifies this interaction.  
A non-trivial case study: (D00673 & hsa:3269) 
D00673 is the KEGG id of drug Ranitidine hydrochloride and hsa:3269 is the KEGG id of protein 
target Histamine H1 receptor (UniProt name HRH1_HUMAN). No interaction is defined between 
D00673 and hsa:3269 in our using gold standard input dataset. 
We first examined the input matrices in two ways to establish that this predicted interaction is non-
trivial. First, we found the interacted targets of D00673 from the drug-target interaction input matrix then 
investigate their similar targets using the target similarity input matrix. Second, we found the interacted 
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drugs of hsa:3269 from the drug-target interaction input matrix and identify similar drugs using the drug-
drug similarity input matrix. 
The only target of D00673 is hsa:3274. The most similar target to hsa:3274 is hsa:3360 and between 
95 distinct targets, hsa:3269 ranks 37th in similarity to hsa:3274. Clearly, the predicted interaction 
(D00673 & hsa:3269) could not be predicted solely through target similarity. 
We then found the drugs predicted to interact with hsa:3269 using the drug-target interaction input 
matrix. Its related drugs are: 
D00234, D00283, D00300, D00364, D00454, D00480, D00493, D00494, D00520, D00521, D00665, 
D00666, D01242, D01295, D01324, D01332, D01713, D01717, D01782, D02327, D02354, D02361, 
D02566, D03621, D04979, D05129. 
The most similar drug toD00673 is D00422. And from above mentioned drugs, the most similar one is 
D00480 which ranks 30th in terms of similarity with D00673. Clearly, the D00673 & hsa:3269 interaction 
could not have bene predicted based on drug similarity alone. 
Now we will show that this prediction is plausible and should be considered as a good candidate for 
experimental validation. As verified by SuperTarget, D00673 now has 14 known targets, two of which are 
HRH2_HUMAN and HRH4_HUMAN. Our predicted target, HRH1_HUMAN, is highly similar to 
HRH4_HUMAN (SuperTarget data and DrugBank documentation clarify their similar aspects).  
6.2.2 Experimental analysis based on independent datasets 
The gold standard data had value in that it enabled us to compare our proposed method with a wide 
variety of methods evaluated using the same data. However, the gold standard data is somewhat obsolete 
(2008) and incomplete (e.g. lacking drug-disease interaction data). We, therefore, created an updated and 
complete dataset to fully evaluate the capabilities of our proposed method, Heter-LP. These data were 
used as input of the proposed method and their results were analyzed.  Here we here discuss one of its 
interesting predictions as a case study.  
 Case study: Osteoarthritis with mild chondrodysplasia 
Osteoarthritis with mild chondrodysplasia is a type of skeletal disease due to the mutation of type II 
procollagen (COL2A1). It causes a progressive degeneration of the articular cartilage of joints with mild 
spinal chondrodysplasia19,20.  
                                                          
19
 “Chondrodysplasia is a heterogeneous group of bone dysplasias, the common characteristic of which is stippling of the epiphyses in infancy.” 
http://medical-dictionary.thefreedictionary.com/chondrodysplasia 
20
 http://www.kegg.jp/kegg/disease/ 
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Table 8 of supplementary materials presents its associated drugs and their corresponding targets (which 
we used as input data). The only known target of this disease is “hsa:1280”  for which there is no known 
drug. The most similar disease (similarity higher than 0.3) to “Osteoarthritis with mild chondrodysplasia” 
and their associated drugs and targets are listed in Table 9 of supplementary materials. 
We have predicted two new drugs for the treatment of this disease: Alendronate sodium, Alendronic acid. 
Alendronate sodium is a salted form of Alendronic acid. And, as expressed in DrugBank, is “for the 
treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women”. 
Its treatment effects have two sides, one by its affinity for hydroxyapatite and the other, its inhibiting 
effect on FPP21 synthase. Hydroxyapatite is part of the mineral matrix of bone and inhibition of FPP will 
inhibit osteoclast activity and reduce bone resorption22. 
In our input datasets both of Alendronate sodium and Alendronic acid are assigned for the treatment of 
Osteoporosis-pseudoglioma syndrome (OPPG), which is a skeletal disease “characterized by severe 
congenital osteoporosis with blindness”23.  
We assert that this prediction is plausible and merits further experimental validation because of the same 
category of “OPPG” and “Osteoarthritis with mild chondrodysplasia” and also the mechanism of action of 
Alendronic acid and Alendronate sodium. It is necessary to mention that this prediction is not a trivial 
one. As you can see in Table 9 of supplementary materials “OPPG” and “Osteoarthritis with mild 
chondrodysplasia” are not similar diseases in input dataset. Also, their input drugs and their input targets 
are not the same. The only target for “OPPG” in input datasets is hsa:4041 and, as mentioned before, the 
only known target of “Osteoarthritis with mild chondrodysplasia” is hsa:1280.  To establish that this 
prediction could not have been made trivially on the basis of drug similarity, we provide a list of most 
similar drugs to “Alendronate” from input dataset in Table 10 of supplementary materials. Clearly, there 
is no similarity between the results in Table 8 and Table 10. No target similarity comparison is 
represented here because of the non-existence of hsa:4041 in input target similarity matrix. 
7 Conclusion and discussion 
    Label propagation is an efficient technique to utilize both local and global features in a network for 
semi-supervised learning [59]. In spite of the growing interest in the use of heterogeneous networks in 
various scientific disciplines, there is insufficient attention being paid to label propagation on these 
                                                          
21
 Farnesyl pyrophosphate 
22
 http://www.drugbank.ca/drugs/DB00630 
23
 http://www.kegg.jp/kegg/disease/ 
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networks. In this paper, we introduce a new label propagation algorithm on heterogeneous networks 
named Heter-LP. Its convergence to an optimal solution is discussed and proved. We had shown that 
there are fewer iteration loops in Heter-LP in comparison to other heterogeneous label propagation 
algorithms and the time complexity is acceptable. 
    The Heter-LP algorithm was applied to the problem of drug repositioning to demonstrate its 
applicability. It was shown that Heter-LP can infer new interactions for disease-drug, drug-target, and 
disease-target relationships successfully through integrating heterogeneous information obtained from 
various types of resources at different levels of biological detail. In fact, we used both local and global 
features together by using label propagation. Furthermore, an advantage of the proposed model is that it 
does not require negative interactions for training, as experimental analysis rarely reports negative 
samples.  
We provide a comprehensive statistical analysis of performance by using of 10-fold cross validation 
testing. The achieved AUC and AUPR outperform most existing state-of-the-art methods for drug 
repositioning. Although these parameters are weaker than some methods in some sense, our designed 
experimental analysis have proven some attractive abilities which there are in some rare practices. It is 
shown that Heter-LP could predict interactions of new drugs, targets and diseases correctly. Moreover, in 
spite of some methods which could predict only trivial interactions, Heter-LP could predict both trivial 
and non-trivial ones.  
  In total, the analysis demonstrates that label propagation is an effective algorithm to predict the new 
drug-target-disease interactions. The possible combination of this approach with network attributes, such 
as topological ones (e.g. different centrality measures) or the addition of more types of data, such as 
anatomical therapeutic chemical (ATC) codes of drugs, and continuous sequence similarities of proteins. 
Lastly, we are confident that performance will continue to increase as more accurate and complete input 
data become available. 
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